NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 248 filers reported holding NEKTAR THERAPEUTICS in Q4 2020. The put-call ratio across all filers is 0.43 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $296,000 | +2.8% | 16,483 | -1.6% | 0.01% | 0.0% |
| Q2 2021 | $288,000 | -16.3% | 16,755 | -2.5% | 0.01% | -14.3% |
| Q1 2021 | $344,000 | +19.0% | 17,192 | +1.1% | 0.01% | 0.0% |
| Q4 2020 | $289,000 | +0.3% | 17,006 | -2.1% | 0.01% | 0.0% |
| Q3 2020 | $288,000 | -30.8% | 17,373 | -3.3% | 0.01% | -36.4% |
| Q2 2020 | $416,000 | +29.2% | 17,960 | -0.6% | 0.01% | +22.2% |
| Q1 2020 | $322,000 | -17.4% | 18,060 | 0.0% | 0.01% | 0.0% |
| Q4 2019 | $390,000 | +20.0% | 18,060 | +1.2% | 0.01% | +28.6% |
| Q3 2019 | $325,000 | -48.8% | 17,839 | 0.0% | 0.01% | -53.3% |
| Q2 2019 | $635,000 | +7.4% | 17,839 | +1.4% | 0.02% | +7.1% |
| Q1 2019 | $591,000 | +3.1% | 17,587 | +0.9% | 0.01% | -6.7% |
| Q4 2018 | $573,000 | -47.1% | 17,431 | -1.9% | 0.02% | -42.3% |
| Q3 2018 | $1,083,000 | +36.1% | 17,760 | +8.9% | 0.03% | +30.0% |
| Q2 2018 | $796,000 | -54.6% | 16,311 | -1.2% | 0.02% | -55.6% |
| Q1 2018 | $1,754,000 | – | 16,511 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |